Product Description
Alvocidib is a synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation. It has a role as an antineoplastic agent, an EC 2.7.11.22 (cyclin-dependent kinase) inhibitor, an antirheumatic drug and an apoptosis inducer. It is a dihydroxyflavone, a hydroxypiperidine, a member of monochlorobenzenes and a tertiary amino compound. It is a conjugate base of an alvocidib(1+). (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Alvocidib)
Mechanisms of Action: CDK9 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Sarcoma|Acute Myeloid Leukemia|Chronic Lymphoid Leukemia|Prolymphocytic Leukemia|Lymphocytic Chronic B-Cell Leukemia|Prolymphocytic B-Cell Leukemia|Multiple Myeloma|Lymphoma, Non-Hodgkin|Mantle-Cell Lymphoma|Endometrial Cancer|Lymphomatoid Granulomatosis|Leukemia, Plasma Cell|Mycosis Fungoides|Liver Cancer|Gastrointestinal Cancer|Acute Monocytic Leukemia|Large-Cell Immunoblastic Lymphoma|Large-Cell Anaplastic Lymphoma|Adenocarcinoma|Renal Cell Carcinoma|Acute Myelomonocytic Leukemia|Sezary Syndrome|Pancreatic Cancer|Kidney Cancer|Waldenstrom Macroglobulinemia|Multiple Sclerosis|Follicular Lymphoma|Esophageal Cancer|Acute Megakaryoblastic Leukemia|Prostate Cancer|B-Cell Marginal Zone Lymphoma|T-Cell Cutaneous Lymphoma|Diffuse Large B-Cell Lymphoma|Melanoma|Acute Erythroblastic Leukemia|Immunoblastic Lymphadenopathy|Adult T-Cell Leukemia-Lymphoma|Acute Eosinophilic Leukemia|Myelodysplastic Syndrome|Preleukemia|Ovarian Cancer|Peritoneal Cancer|Hypereosinophilic Syndrome|Breast Cancer|Testicular Cancer|Squamous Cell Carcinoma|Acute Basophilic Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Head and Neck Cancer|Acute Lymphoid Leukemia|Seminoma|Thromboembolism|Germinoma|Lymphoma, B-Cell
Phase 1: Oncology Solid Tumor Unspecified|Chronic Lymphoid Leukemia|Anemia, Refractory|Blast Crisis|Chronic Myeloid Leukemia|Sarcoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Myeloid Leukemia|Adenocarcinoma|Prolymphocytic Leukemia|Pancreatic Cancer|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Anemia, Refractory, with Excess of Blasts|Lymphocytic Chronic B-Cell Leukemia|Prolymphocytic B-Cell Leukemia|Acute Lymphoid Leukemia|Thrombocytopenia|Melanoma|Breast Cancer|Lymphoma, B-Cell|Prostate Cancer|Gastrointestinal Stromal Tumors|Lymphoma, Non-Hodgkin|Embryonal Rhabdomyosarcoma|Oncology Hematological Unspecified|Skin Cancer|Osteosarcoma|Cerebellar Cancer|Ependymoma|Retinoblastoma|Sarcoma, Ewing|Hypereosinophilic Syndrome|Acute Myelomonocytic Leukemia|Acute Erythroblastic Leukemia|Kidney Cancer|Brain Stem Cancer|Chronic Myelomonocytic Leukemia|Hypothalamic Cancer|Astrocytoma|Acute Eosinophilic Leukemia|Optic Nerve Cancer|Peripheral Neuroectodermal Tumors, Primitive|Optic Nerve Glioma|Lymphoid Leukemia|Soft Tissue Cancer|Medulloblastoma|Neuroblastoma|Wilms Tumor|Primitive Neuroectodermal Tumors|Liver Cancer|B-Cell Marginal Zone Lymphoma|Male Breast Cancer|Hairy Cell Leukemia|Mantle-Cell Lymphoma|Acute Monocytic Leukemia|Esophageal Cancer|Mesothelioma|Acute Megakaryoblastic Leukemia|Waldenstrom Macroglobulinemia|Follicular Lymphoma|Lymphoproliferative Disorders|Leukemia|Multiple Myeloma|Intestinal Cancer|Acute Basophilic Leukemia|Lymphoma|Kidney Diseases|Supratentorial Cancer|Diffuse Large B-Cell Lymphoma|Non-Small-Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2017-001178-41 | P2 |
Terminated |
Acute Myeloid Leukemia |
2021-10-10 |
|
| TPI-ALV-102 | P2 |
Terminated |
Myelodysplastic Syndrome|Preleukemia |
2021-08-16 |
|
| TPI-ALV-202 | P2 |
Terminated |
Acute Myeloid Leukemia |
2021-04-22 |
|
| M16-186 | P1 |
Completed |
Acute Myeloid Leukemia |
2021-01-25 |
41% |